Key Drivers
- Strong Liquidity
- No Revenue
- Negative Cash Flow
AIAI Summary
ELVN's huge cash cushion and zero debt remove financing risk, but the stock is now essentially a binary bet on whether ELVN-001 can turn its Phase 1 promise into a registrational Phase 3 success, so investors should treat it as a high-upside catalyst play with sharp downside if clinical progress slips.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Negative Cash Flow
ELVN's balance sheet is exceptionally strong and debt-free, but persistent losses, negative cash flow, and no revenue continue to limit its investment appeal.
Price Behavior
Key Price Behavior Insights:
- •Breakout confirmed
- •High-50s support
- •Momentum pause
ELVN stayed in a constructive uptrend last month, breaking above $54-$55 and holding the high-$50s, but momentum has paused below $61.11.
Sharp breakout above $54-$55 then stalled below $61.11, suggesting consolidation after the advance
Sentiment & News
Key News Insights:
- •Institutional buying
- •Phase 1 progress
- •Cash runway
Enliven Therapeutics is gaining momentum as major investors boost stakes, ELVN-001 posts encouraging Phase 1 CML data, and its $895M cash position supports development through 2030.
This is a positive catalyst mix for $ELVN, improving investor confidence while de-risking the clinical and financing outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings